The company had reported net profit of Rs 74.43 crore during the January-March same period of the 2012-13 fiscal.
Net sales of the company during Q4, 2013-14 were Rs 739.81 crore, up 12.32% from Rs 658.64 crore in the year-ago period, Ipca Laboratories said in a filing to the BSE.
Also Read
The company's Q4 revenue from domestic formulations business stood at Rs 196.56 crore, up 10%, while the revenue from exports stood at Rs 373.18 crore, up 19%.
The Ipca Labs scrip was trading at Rs 785 on the BSE in the afternoon trade, down 0.39% from the previous close.